The influence of cardiac output distribution on the tissue/plasma drug concentration ratio

2002 ◽  
Vol 27 (2) ◽  
pp. 79-81 ◽  
Author(s):  
Pietro Fagiolino
Keyword(s):  
Cardiac Output ◽  
Drug Concentration ◽  
Concentration Ratio ◽  
Plasma Drug Concentration ◽  
Plasma Drug ◽  
Output Distribution ◽  
Cardiac Output Distribution

Prediction of human blood-to-plasma drug concentration ratio

2010 ◽  
pp. n/a-n/a ◽  
Author(s):  
Takahide Uchimura ◽  
Motohiro Kato ◽  
Tomohisa Saito ◽  
Haruki Kinoshita
Keyword(s):  
Human Blood ◽  
Drug Concentration ◽  
Concentration Ratio ◽  
Plasma Drug Concentration ◽  
Plasma Drug

Exploring In Silico Prediction of the Unbound Brain-to-Plasma Drug Concentration Ratio: Model Validation, Renewal, and Interpretation

2015 ◽  
Vol 104 (3) ◽  
pp. 1197-1206 ◽  
Author(s):  
Srinidhi Varadharajan ◽  
Susanne Winiwarter ◽  
Lars Carlsson ◽  
Ola Engkvist ◽  
Ajay Anantha ◽  
...  
Keyword(s):  
Model Validation ◽  
Drug Concentration ◽  
In Silico ◽  
Concentration Ratio ◽  
Plasma Drug Concentration ◽  
Ratio Model ◽  
In Silico Prediction ◽  
Plasma Drug

scholarly journals Preparation and Pharmacokinetic Study of Daidzein Long-Circulating Liposomes

2019 ◽  
Vol 14 (1) ◽  
Author(s):  
Qiao Wang ◽  
Wenjin Liu ◽  
Junjun Wang ◽  
Hong Liu ◽  
Yong Chen
Keyword(s):  
Single Dose ◽  
Drug Concentration ◽  
Drug Loading ◽  
Plasma Drug Concentration ◽  
The Body ◽  
Molar Ratio ◽  
Terminal Phase ◽  
Plasma Drug ◽  
Ultrasonic Time ◽  
Time Required

Abstract In this study, daidzein long-circulating liposomes (DLCL) were prepared using the ultrasonication and lipid film-hydration method. The optimized preparation conditions by the orthogonal design was as follows: 55 to 40 for the molar ratio of soybean phosphatidylcholine (SPC) to cholesterol, 1 to 10 for the mass ratio of daidzein to total lipid (SPC and cholesterol) (w:w), the indicated concentration of 5% DSPE-mPEG2000 (w:w), 50 °C for the hydration temperature, and 24 min for the ultrasonic time. Under these conditions, the encapsulation efficiency and drug loading of DLCL were 85.3 ± 3.6% and 8.2 ± 1.4%, respectively. The complete release times of DLCL in the medium of pH 1.2 and pH 6.9 increased by four- and twofold of that of free drugs, respectively. After rats were orally administered, a single dose of daidzein (30 mg/kg) and DLCL (containing equal dose of daidzein), respectively, and the MRT0−t (mean residence time, which is the time required for the elimination of 63.2% of drug in the body), t1/2 (the elimination half-life, which is the time required to halve the plasma drug concentration of the terminal phase), and AUC0−t (the area under the plasma drug concentration-time curve, which represents the total absorption after a single dose and reflects the drug absorption degree) of daidzein in DLCL group, increased by 1.6-, 1.8- and 2.5-fold as compared with those in the free group daidzein. Our results indicated that DLCL could not only reduce the first-pass effect of daidzein to promote its oral absorption, but also prolong its mean resident time to achieve the slow-release effect.

Cardiac Output Distribution after Left Colon Anastomosis in the Rat

1979 ◽  
Vol 11 (2) ◽  
pp. 134-144 ◽  
Author(s):  
H. Jiborn ◽  
J. Ahonen ◽  
B. Lindell ◽  
B. Zederfeldt
Keyword(s):  
Cardiac Output ◽  
Left Colon ◽  
Colon Anastomosis ◽  
Output Distribution ◽  
Cardiac Output Distribution

scholarly journals Evaluation of the pharmacokinetic interaction and safety of ubrogepant coadministered with acetaminophen or nonsteroidal anti-inflammatory drugs: A randomized trial

2020 ◽  
Vol 3 ◽  
pp. 251581632092118 ◽  
Author(s):  
Abhijeet Jakate ◽  
Ramesh Boinpally ◽  
Matthew Butler ◽  
Kaifeng Lu ◽  
Kristi Womack ◽  
...  
Keyword(s):  
Drug Concentration ◽  
Geometric Mean ◽  
Plasma Drug Concentration ◽  
Migraine Treatment ◽  
Maximum Plasma ◽  
Plasma Drug ◽  
Two Phase ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
Healthy Participants

Background: Ubrogepant is a novel, oral calcitonin gene–related peptide receptor antagonist approved by the US Food and Drug Administration for acute treatment of migraine with or without aura in adults. Objectives: To assess potential pharmacokinetic (PK) drug–drug interactions in healthy participants and inform the safety and tolerability of ubrogepant alone and in combination with acetaminophen or nonsteroidal anti-inflammatory drugs (NSAIDs) in healthy participants and participants with migraine. Methods: Two phase 1, three-way crossover studies randomized healthy adults to 100 mg ubrogepant alone, 1000 mg acetaminophen or 500 mg naproxen alone, and 100 mg ubrogepant plus 1000 mg acetaminophen or 500 mg naproxen. Geometric mean ratios (GMRs) and 90% confidence intervals were calculated based on statistical comparison of maximum plasma drug concentration ( C max) and area under the plasma drug concentration–time curve (AUC) for treatment in combination versus alone. Two phase 3 randomized trials included adults with migraine. Treatment-emergent adverse events (TEAEs) were evaluated. Results: Time to C max and terminal elimination half-life for all treatments were unchanged when coadministered. Ubrogepant C max and AUC increased by approximately 40% when coadministered with acetaminophen. Acetaminophen C max decreased by 24% (GMR = 0.76) when coadministered with ubrogepant. There were no significant PK interactions between ubrogepant and naproxen. TEAE rates in the acetaminophen and NSAID rescue medication groups were similar to ubrogepant alone. Conclusions: Coadministration of ubrogepant and acetaminophen resulted in a statistically significant increase in ubrogepant exposure and a decrease in acetaminophen C max; however, these changes were not clinically relevant. No statistically or clinically relevant changes in PK were associated with ubrogepant and naproxen coadministration. No safety concerns were identified for ubrogepant alone or in combination with acetaminophen or NSAIDs.

Sign in / Sign up

Export Citation Format

Share Document